

Supplementary Materials for Consolidated Financial Results for Fiscal Year 2015. 12 (IFRS)

Innovation all for the patients



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts
3. Exchange rates used for each period are as follows.

QTR

(Yen)

Average		Actual				Actual			
		FY2014				FY2015			
		1-3	4-6	7-9	10-12	1-3	4-6	7-9	10-12
		QTR	QTR	QTR	QTR	QTR	QTR	QTR	QTR
CHF		115.17	114.91	113.72	118.74	124.98	128.80	126.71	122.62
EUR		140.90	140.12	137.79	143.01	134.38	134.16	135.94	132.99
USD		102.81	102.16	103.92	114.47	119.15	121.32	122.20	121.47
SGD		81.03	81.56	83.04	88.38	87.88	90.33	87.89	86.29

YTD

Average	Actual	Actual				Actual				Forecast
	FY2013	FY2014				FY2015				FY2016
	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
CHF	105.24	115.17	115.04	114.59	115.69	124.98	126.88	126.82	125.74	127.00
EUR	129.51	140.90	140.51	139.58	140.49	134.38	134.27	134.83	134.36	134.00
USD	97.54	102.81	102.49	102.96	105.84	119.15	120.24	120.89	121.03	120.00
SGD	77.97	81.03	81.29	81.87	83.54	87.88	89.10	88.69	88.07	87.00

Period-end

As of	Actual	Actual				Actual			
	FY2013	FY2014				FY2015			
	31 Dec.	31 Mar.	30 Jun.	30 Sep.	31 Dec.	31 Mar.	30 Jun.	30 Sep.	31 Dec.
CHF	118.42	115.93	113.79	115.08	120.81	124.13	132.49	123.25	121.89
EUR	145.16	141.40	138.37	138.88	145.26	130.09	137.69	134.69	131.75
USD	105.16	102.82	101.38	109.49	119.48	120.08	122.54	119.74	120.52
SGD	82.96	81.70	81.12	85.94	90.41	87.24	91.03	83.85	85.20

Financial highlights (YTD)

(Billions of yen)

	Actual	Actual				Actual							
	FY2013	FY2014				FY2015							
	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD	
Revenues	423.7	124.0	222.0	333.4	461.1	117.1	(5.6)	240.2	+8.2	367.8	+10.3	498.8	+8.2
Sales	401.3	114.2	208.1	315.1	436.9	113.4	(0.7)	232.6	+11.8	353.3	+12.1	468.4	+7.2
excl. Tamiflu	390.2	107.3	201.0	308.0	423.8	106.7	(0.6)	225.9	+12.4	346.5	+12.5	460.2	+8.6
Domestic	329.2	85.2	165.3	254.2	349.5	83.9	(1.5)	179.1	+8.3	275.4	+8.3	378.0	+8.2
Sales to Roche	42.9	16.9	26.3	39.5	55.1	18.0	+6.5	37.2	+41.4	56.3	+42.5	63.1	+14.5
Overseas	18.1	5.2	9.5	14.3	19.3	4.8	(7.7)	9.6	+1.1	14.7	+2.8	19.1	(1.0)
Tamiflu sales	11.0	6.9	7.1	7.2	13.0	6.7	(2.9)	6.7	(5.6)	6.7	(6.9)	8.2	(36.9)
Ordinary use	10.1	6.8	7.0	7.0	12.9	6.7	(1.5)	6.7	(4.3)	6.7	(4.3)	8.2	(36.4)
Govt. stockpiles etc.	0.9	0.1	0.1	0.2	0.2	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)
Royalties and other operating income	22.4	9.8	13.9	18.3	24.2	3.7	(62.2)	7.5	(46.0)	14.5	(20.8)	30.4	+25.6
Cost of sales	(187.0)	(55.5)	(102.6)	(157.3)	(218.1)	(57.7)	+4.0	(117.2)	+14.2	(178.7)	+13.6	(240.2)	+10.1
(% of Sales)	46.6	48.6	49.3	49.9	49.9	50.9	—	50.4	—	50.6	—	51.3	—
Gross profit	236.7	68.5	119.4	176.1	243.0	59.3	(13.4)	122.9	+2.9	189.0	+7.3	258.6	+6.4
(% of Revenues)	55.9	55.2	53.8	52.8	52.7	50.6	—	51.2	—	51.4	—	51.8	—
Operating expenses	(157.9)	(37.5)	(76.3)	(117.0)	(167.2)	(38.6)	+2.9	(79.7)	+4.5	(122.0)	+4.3	(171.8)	+2.8
(% of Revenues)	37.3	30.2	34.4	35.1	36.3	33.0	—	33.2	—	33.2	—	34.4	—
Marketing and distribution	(71.6)	(16.6)	(34.3)	(51.7)	(71.7)	(16.6)	0.0	(34.7)	+1.2	(52.1)	+0.8	(74.8)	+4.3
(% of Revenues)	16.9	13.4	15.5	15.5	15.5	14.2	—	14.4	—	14.2	—	15.0	—
Research and development	(74.3)	(18.3)	(36.7)	(55.5)	(80.8)	(19.0)	+3.8	(39.2)	+6.8	(60.7)	+9.4	(83.8)	+3.7
(% of Revenues)	17.5	14.8	16.5	16.6	17.5	16.2	—	16.3	—	16.5	—	16.8	—
General and administration	(12.1)	(2.6)	(5.2)	(9.7)	(14.6)	(3.0)	+15.4	(5.9)	+13.5	(9.1)	(6.2)	(13.2)	(9.6)
(% of Revenues)	2.9	2.1	2.3	2.9	3.2	2.6	—	2.5	—	2.5	—	2.6	—
Operating profit	78.7	31.1	43.1	59.1	75.9	20.7	(33.4)	43.2	+0.2	67.1	+13.5	86.8	+14.4
(% of Revenues)	18.6	25.1	19.4	17.7	16.5	17.7	—	18.0	—	18.2	—	17.4	—
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.1)	—	(0.1)	—
Other financial income (expense)	(1.8)	0.2	0.3	0.3	0.3	0.5	+150.0	0.7	+133.3	0.4	+33.3	0.6	+100.0
Profit before taxes	76.9	31.3	43.4	59.4	76.2	21.2	(32.3)	43.9	+1.2	67.4	+13.5	87.3	+14.6
(% of Revenues)	18.1	25.2	19.5	17.8	16.5	18.1	—	18.3	—	18.3	—	17.5	—
Income taxes	(25.1)	(12.2)	(14.0)	(18.8)	(24.1)	(6.4)	(47.5)	(13.1)	(6.4)	(18.8)	0.0	(24.9)	+3.3
Net income	51.9	19.1	29.4	40.6	52.1	14.8	(22.5)	30.8	+4.8	48.6	+19.7	62.4	+19.8
(% of Revenues)	12.2	15.4	13.2	12.2	11.3	12.6	—	12.8	—	13.2	—	12.5	—
Attributable to													
Chugai shareholders	50.9	18.8	28.9	39.7	51.0	14.6	(22.3)	30.1	+4.2	47.6	+19.9	61.1	+19.8
Non-controlling interests	1.0	0.3	0.5	0.8	1.1	0.2	(33.3)	0.7	+40.0	0.9	+12.5	1.2	+9.1
Earnings per share													
Basic (yen)	93.47	34.46	53.03	72.90	93.53	26.73	(22.4)	55.24	+4.2	87.31	+19.8	112.00	+19.7
Diluted (yen)	93.35	34.41	52.95	72.79	93.38	26.68	(22.5)	55.13	+4.1	87.15	+19.7	111.79	+19.7

Other financial income (expense) includes net amount of FX related gains/losses.

Financial highlights (QTR)

(Billions of yen)

	Actual				Actual							
	FY2014				FY2015							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	124.0	98.0	111.4	127.7	117.1	(5.6)	123.1	+25.6	127.6	+14.5	131.1	+2.7
Sales	114.2	93.9	107.0	121.7	113.4	(0.7)	119.2	+26.9	120.6	+12.7	115.2	(5.3)
excl. Tamiflu	107.3	93.7	106.9	115.9	106.7	(0.6)	119.2	+27.2	120.6	+12.8	113.7	(1.9)
Domestic	85.2	80.1	88.9	95.3	83.9	(1.5)	95.2	+18.9	96.3	+8.3	102.6	+7.7
Sales to Roche	16.9	9.3	13.2	15.6	18.0	+6.5	19.2	+106.5	19.1	+44.7	6.7	(57.1)
Overseas	5.2	4.3	4.8	5.0	4.8	(7.7)	4.8	+11.6	5.2	+8.3	4.4	(12.0)
Tamiflu sales	6.9	0.2	0.1	5.8	6.7	(2.9)	0.0	(100.0)	0.0	(100.0)	1.5	(74.1)
Ordinary use	6.8	0.2	0.0	5.8	6.7	(1.5)	0.0	(100.0)	0.0	0.0	1.5	(74.1)
Govt. stockpiles etc.	0.1	–	0.1	0.0	0.0	(100.0)	–	–	–	(100.0)	0.0	0.0
Royalties and other operating income	9.8	4.1	4.4	5.9	3.7	(62.2)	3.9	(4.9)	7.0	+59.1	15.9	+169.5
Cost of sales	(55.5)	(47.1)	(54.7)	(60.7)	(57.7)	+4.0	(59.5)	+26.3	(61.5)	+12.4	(61.5)	+1.3
(% of Sales)	48.6	50.2	51.1	49.9	50.9	–	49.9	–	51.0	–	53.4	–
Gross profit	68.5	50.9	56.7	66.9	59.3	(13.4)	63.6	+25.0	66.1	+16.6	69.6	+4.0
(% of Revenues)	55.2	51.9	50.9	52.4	50.6	–	51.7	–	51.8	–	53.1	–
Operating expenses	(37.5)	(38.8)	(40.7)	(50.2)	(38.6)	+2.9	(41.1)	+5.9	(42.3)	+3.9	(49.8)	(0.8)
(% of Revenues)	30.2	39.6	36.5	39.3	33.0	–	33.4	–	33.2	–	38.0	–
Marketing and distribution	(16.6)	(17.7)	(17.4)	(20.0)	(16.6)	0.0	(18.1)	+2.3	(17.5)	+0.6	(22.7)	+13.5
(% of Revenues)	13.4	18.1	15.6	15.7	14.2	–	14.7	–	13.7	–	17.3	–
Research and development	(18.3)	(18.4)	(18.8)	(25.3)	(19.0)	+3.8	(20.2)	+9.8	(21.5)	+14.4	(23.1)	(8.7)
(% of Revenues)	14.8	18.8	16.9	19.8	16.2	–	16.4	–	16.8	–	17.6	–
General and administration	(2.6)	(2.7)	(4.5)	(4.9)	(3.0)	+15.4	(2.9)	+7.4	(3.3)	(26.7)	(4.1)	(16.3)
(% of Revenues)	2.1	2.8	4.0	3.8	2.6	–	2.4	–	2.6	–	3.1	–
Operating profit	31.1	12.0	16.0	16.7	20.7	(33.4)	22.5	+87.5	23.8	+48.8	19.7	+18.0
(% of Revenues)	25.1	12.2	14.4	13.1	17.7	–	18.3	–	18.7	–	15.0	–
Financing costs	(0.0)	0.0	0.0	0.0	(0.0)	0.0	(0.0)	–	(0.0)	–	(0.0)	–
Other financial income (expense)	0.2	0.1	(0.0)	0.0	0.5	+150.0	0.2	+100.0	(0.3)	–	0.2	–
Profit before taxes	31.3	12.2	16.0	16.7	21.2	(32.3)	22.7	+86.1	23.5	+46.9	19.9	+19.2
(% of Revenues)	25.2	12.4	14.4	13.1	18.1	–	18.4	–	18.4	–	15.2	–
Income taxes	(12.2)	(1.8)	(4.8)	(5.2)	(6.4)	(47.5)	(6.7)	+272.2	(5.7)	+18.8	(6.1)	+17.3
Net income	19.1	10.3	11.1	11.5	14.8	(22.5)	16.0	+55.3	17.8	+60.4	13.8	+20.0
(% of Revenues)	15.4	10.5	10.0	9.0	12.6	–	13.0	–	13.9	–	10.5	–
Attributable to												
Chugai shareholders	18.8	10.1	10.8	11.3	14.6	(22.3)	15.6	+54.5	17.5	+62.0	13.5	+19.5
Non-controlling interests	0.3	0.2	0.3	0.3	0.2	(33.3)	0.4	+100.0	0.3	0.0	0.3	0.0
Earnings per share												
Basic (yen)	34.46	18.57	19.87	20.63	26.73	(22.4)	28.51	+53.5	32.07	+61.4	24.69	+19.7
Diluted (yen)	34.41	18.54	19.84	20.60	26.68	(22.5)	28.45	+53.5	32.01	+61.3	24.65	+19.7

Other financial income (expense) includes net amount of FX related gains/losses.

Financial highlights (Core results YTD)

(Billions of yen)

	Actual	Actual				Actual								Forecast (Jan 28th Announced)	
	FY2013	FY2014				FY2015								FY2016	
	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		YTD	
Revenues	423.7	124.0	222.0	333.4	461.1	117.1	(5.6)	240.2	+8.2	367.8	+10.3	498.8	+8.2	495.0	(0.8)
Sales	401.3	114.2	208.1	315.1	436.9	113.4	(0.7)	232.6	+11.8	353.3	+12.1	468.4	+7.2	475.4	+1.5
excl. Tamiflu	390.2	107.3	201.0	308.0	423.8	106.7	(0.6)	225.9	+12.4	346.5	+12.5	460.2	+8.6	466.8	+1.4
Domestic	329.2	85.2	165.3	254.2	349.5	83.9	(1.5)	179.1	+8.3	275.4	+8.3	378.0	+8.2	379.0	+0.3
Sales to Roche	42.9	16.9	26.3	39.5	55.1	18.0	+6.5	37.2	+41.4	56.3	+42.5	63.1	+14.5	70.5	+11.7
Overseas	18.1	5.2	9.5	14.3	19.3	4.8	(7.7)	9.6	+1.1	14.7	+2.8	19.1	(1.0)	17.3	(9.4)
Tamiflu sales	11.0	6.9	7.1	7.2	13.0	6.7	(2.9)	6.7	(5.6)	6.7	(6.9)	8.2	(36.9)	8.6	+4.9
Ordinary use	10.1	6.8	7.0	7.0	12.9	6.7	(1.5)	6.7	(4.3)	6.7	(4.3)	8.2	(36.4)	7.6	(7.3)
Govt. stockpiles etc.	0.9	0.1	0.1	0.2	0.2	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	1.0	–
Royalties and other operating income	22.4	9.8	13.9	18.3	24.2	3.7	(62.2)	7.5	(46.0)	14.5	(20.8)	30.4	+25.6	19.6	(35.5)
Cost of sales	(186.1)	(55.3)	(102.1)	(156.5)	(217.0)	(57.4)	+3.8	(116.6)	+14.2	(177.7)	+13.5	(238.9)	+10.1	(254.0)	+6.3
(% of Sales)	46.4	48.4	49.1	49.7	49.7	50.6	–	50.1	–	50.3	–	51.0	–	53.4	–
Gross profit	237.6	68.8	119.9	176.9	244.2	59.7	(13.2)	123.6	+3.1	190.1	+7.5	260.0	+6.5	241.0	(7.3)
(% of Revenues)	56.1	55.5	54.0	53.1	53.0	51.0	–	51.5	–	51.7	–	52.1	–	48.7	–
Operating expenses	(157.7)	(37.3)	(76.2)	(116.9)	(166.8)	(38.2)	+2.4	(77.7)	+2.0	(119.8)	+2.5	(169.3)	+1.5	(170.0)	+0.4
(% of Revenues)	37.2	30.1	34.3	35.1	36.2	32.6	–	32.3	–	32.6	–	33.9	–	34.3	–
Marketing and distribution	(71.5)	(16.6)	(34.3)	(51.7)	(71.7)	(16.6)	0.0	(34.6)	+0.9	(52.0)	+0.6	(74.7)	+4.2		
(% of Revenues)	16.9	13.4	15.5	15.5	15.5	14.2	–	14.4	–	14.1	–	15.0	–		
Research and development	(74.1)	(18.2)	(36.6)	(55.4)	(80.6)	(18.6)	+2.2	(37.3)	+1.9	(58.8)	+6.1	(81.9)	+1.6		
(% of Revenues)	17.5	14.7	16.5	16.6	17.5	15.9	–	15.5	–	16.0	–	16.4	–		
General and administration	(12.1)	(2.6)	(5.2)	(9.7)	(14.6)	(3.0)	+15.4	(5.8)	+11.5	(8.9)	(8.2)	(12.8)	(12.3)		
(% of Revenues)	2.9	2.1	2.3	2.9	3.2	2.6	–	2.4	–	2.4	–	2.6	–		
Operating profit	79.9	31.4	43.7	60.1	77.3	21.5	(31.5)	45.9	+5.0	70.3	+17.0	90.7	+17.3	71.0	(21.7)
(% of Revenues)	18.9	25.3	19.7	18.0	16.8	18.4	–	19.1	–	19.1	–	18.2	–	14.3	–
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.1)	–	(0.1)	–		
Other financial income (expense)	(1.8)	0.2	0.3	0.3	0.3	0.5	+150.0	0.7	+133.3	0.4	+33.3	0.6	+100.0		
Profit before taxes	78.1	31.6	44.1	60.4	77.6	21.9	(30.7)	46.5	+5.4	70.6	+16.9	91.2	+17.5		
(% of Revenues)	18.4	25.5	19.9	18.1	16.8	18.7	–	19.4	–	19.2	–	18.3	–		
Income taxes	(25.5)	(12.3)	(14.2)	(19.2)	(24.6)	(6.6)	(46.3)	(14.0)	(1.4)	(20.0)	+4.2	(26.3)	+6.9		
Net income	52.6	19.3	29.8	41.2	53.0	15.3	(20.7)	32.5	+9.1	50.7	+23.1	64.9	+22.5		
(% of Revenues)	12.4	15.6	13.4	12.4	11.5	13.1	–	13.5	–	13.8	–	13.0	–		
Attributable to															
Chugai shareholders	51.6	19.0	29.3	40.3	51.9	15.1	(20.5)	31.9	+8.9	49.8	+23.6	63.7	+22.7		
Non-controlling interests	1.0	0.3	0.5	0.8	1.1	0.2	(33.3)	0.7	+40.0	0.9	+12.5	1.2	+9.1		
Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares)	545	546	546	546	546	547	+0.2	547	+0.2	547	+0.2	547	+0.2		
Core earnings per share (diluted) (yen)	94.69	34.82	53.66	73.85	95.04	27.54	(20.9)	58.30	+8.6	91.01	+23.2	116.42	+22.5	92.54	(20.5)
Core payout ratio (%)	47.5				50.5							49.8		56.2	–
Dividend per share (Full year) (yen)	45				48							58		52	–
Dividend per share (Half year) (yen)	22				22							26		26	–

Please see page 5 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Financial highlights (Core results QTR)

(Billions of yen)

	Actual				Actual							
	FY2014				FY2015							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	124.0	98.0	111.4	127.7	117.1	(5.6)	123.1	+25.6	127.6	+14.5	131.1	+2.7
Sales	114.2	93.9	107.0	121.7	113.4	(0.7)	119.2	+26.9	120.6	+12.7	115.2	(5.3)
excl. Tamiflu	107.3	93.7	106.9	115.9	106.7	(0.6)	119.2	+27.2	120.6	+12.8	113.7	(1.9)
Domestic	85.2	80.1	88.9	95.3	83.9	(1.5)	95.2	+18.9	96.3	+8.3	102.6	+7.7
Sales to Roche	16.9	9.3	13.2	15.6	18.0	+6.5	19.2	+106.5	19.1	+44.7	6.7	(57.1)
Overseas	5.2	4.3	4.8	5.0	4.8	(7.7)	4.8	+11.6	5.2	+8.3	4.4	(12.0)
Tamiflu sales	6.9	0.2	0.1	5.8	6.7	(2.9)	0.0	(100.0)	0.0	(100.0)	1.5	(74.1)
Ordinary use	6.8	0.2	0.0	5.8	6.7	(1.5)	0.0	(100.0)	0.0	0.0	1.5	(74.1)
Govt. stockpiles etc.	0.1	–	0.1	0.0	0.0	(100.0)	–	–	–	(100.0)	0.0	0.0
Royalties and other operating income	9.8	4.1	4.4	5.9	3.7	(62.2)	3.9	(4.9)	7.0	+59.1	15.9	+169.5
Cost of sales	(55.3)	(46.8)	(54.4)	(60.5)	(57.4)	+3.8	(59.1)	+26.3	(61.1)	+12.3	(61.2)	+1.2
(% of Sales)	48.4	49.8	50.8	49.7	50.6	–	49.6	–	50.7	–	53.1	–
Gross profit	68.8	51.1	57.0	67.2	59.7	(13.2)	63.9	+25.0	66.5	+16.7	69.9	+4.0
(% of Revenues)	55.5	52.1	51.2	52.6	51.0	–	51.9	–	52.1	–	53.3	–
Operating expenses	(37.3)	(38.9)	(40.7)	(50.0)	(38.2)	+2.4	(39.5)	+1.5	(42.0)	+3.2	(49.5)	(1.0)
(% of Revenues)	30.1	39.7	36.5	39.2	32.6	–	32.1	–	32.9	–	37.8	–
Marketing and distribution	(16.6)	(17.7)	(17.4)	(20.0)	(16.6)	0.0	(18.0)	+1.7	(17.4)	0.0	(22.6)	+13.0
(% of Revenues)	13.4	18.1	15.6	15.7	14.2	–	14.6	–	13.6	–	17.2	–
Research and development	(18.2)	(18.4)	(18.8)	(25.1)	(18.6)	+2.2	(18.7)	+1.6	(21.5)	+14.4	(23.1)	(8.0)
(% of Revenues)	14.7	18.8	16.9	19.7	15.9	–	15.2	–	16.8	–	17.6	–
General and administration	(2.6)	(2.7)	(4.5)	(4.9)	(3.0)	+15.4	(2.8)	+3.7	(3.1)	(31.1)	(3.8)	(22.4)
(% of Revenues)	2.1	2.8	4.0	3.8	2.6	–	2.3	–	2.4	–	2.9	–
Operating profit	31.4	12.3	16.3	17.2	21.5	(31.5)	24.4	+98.4	24.4	+49.7	20.4	+18.6
(% of Revenues)	25.3	12.6	14.6	13.5	18.4	–	19.8	–	19.1	–	15.6	–
Financing costs	(0.0)	0.0	0.0	0.0	(0.0)	0.0	(0.0)	–	(0.0)	–	(0.0)	–
Other financial income (expense)	0.2	0.1	(0.0)	0.0	0.5	+150.0	0.2	+100.0	(0.3)	–	0.2	–
Profit before taxes	31.6	12.4	16.3	17.3	21.9	(30.7)	24.6	+98.4	24.1	+47.9	20.5	+18.5
(% of Revenues)	25.5	12.7	14.6	13.5	18.7	–	20.0	–	18.9	–	15.6	–
Income taxes	(12.3)	(1.9)	(5.0)	(5.4)	(6.6)	(46.3)	(7.4)	+289.5	(6.0)	+20.0	(6.3)	+16.7
Net income	19.3	10.5	11.3	11.8	15.3	(20.7)	17.2	+63.8	18.2	+61.1	14.2	+20.3
(% of Revenues)	15.6	10.7	10.1	9.2	13.1	–	14.0	–	14.3	–	10.8	–
Attributable to												
Chugai shareholders	19.0	10.3	11.0	11.6	15.1	(20.5)	16.8	+63.1	17.9	+62.7	13.9	+19.8
Non-controlling interests	0.3	0.2	0.3	0.3	0.2	(33.3)	0.4	+100.0	0.3	0.0	0.3	0.0
Core earnings per share (diluted) (yen)	34.82	18.85	20.19	21.19	27.54	(20.9)	30.76	+63.2	32.71	+62.0	25.42	+20.0

Other financial income (expense) includes net amount of FX related gains/losses.

Reconciliation of IFRS results to Core results

(Billions of yen)

	FY2014				FY2015			
	1-12				1-12			
	IFRS results	Intangible assets	Others	Core results	IFRS results	Intangible assets	Others	Core results
Revenues	461.1	–	–	461.1	498.8	–	–	498.8
Sales	436.9	–	–	436.9	468.4	–	–	468.4
Royalties and other operating income	24.2	–	–	24.2	30.4	–	–	30.4
Cost of sales	(218.1)	1.1	–	(217.0)	(240.2)	1.4	–	(238.9)
Gross profit	243.0	1.1	–	244.2	258.6	1.4	–	260.0
Operating expenses	(167.2)	0.2	0.1	(166.8)	(171.8)	2.1	0.5	(169.3)
Marketing and distribution	(71.7)	0.1	–	(71.7)	(74.8)	0.2	–	(74.7)
Research and development	(80.8)	0.2	0.1	(80.6)	(83.8)	1.9	–	(81.9)
General and administration	(14.6)	–	0.0	(14.6)	(13.2)	–	0.5	(12.8)
Operating profit	75.9	1.4	0.1	77.3	86.8	3.5	0.5	90.7
Financing costs	(0.0)	–	–	(0.0)	(0.1)	–	–	(0.1)
Other financial income (expense)	0.3	–	–	0.3	0.6	–	–	0.6
Profit before taxes	76.2	1.4	0.1	77.6	87.3	3.5	0.5	91.2
Income taxes	(24.1)	(0.5)	(0.0)	(24.6)	(24.9)	(1.2)	(0.2)	(26.3)
Net income	52.1	0.8	0.1	53.0	62.4	2.2	0.3	64.9
Attributable to								
Chugai shareholders	51.0	0.8	0.1	51.9	61.1	2.2	0.3	63.7
Non-controlling interests	1.1	–	–	1.1	1.2	–	–	1.2

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting non-Core items to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and as the basis for payment-by-results such as a return to shareholders.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization of intangible assets (1.2 billion yen in 2014 and 1.6 billion yen in 2015)

Impairment of intangible assets (0.2 billion yen in 2014 and 1.9 billion yen in 2015)

Others

Restructuring expenses (0.1 billion yen in 2014 and immaterial in 2015)

Environmental costs (immaterial in 2014 and 0.5 billion yen in 2015)

Statements of revenues (YTD)

(Billions of yen)

		Actual	Actual				Actual									Forecast (Jan 28th announced)	
		FY2013	FY2014				FY2015									FY2016	
		1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)	
		YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Full-year		
Sales		401.3	114.2	208.1	315.1	436.9	113.4	(0.7)	232.6	+11.8	353.3	+12.1	468.4	+7.2	475.4	+1.5	
Excl. Tamiflu		390.2	107.3	201.0	308.0	423.8	106.7	(0.6)	225.9	+12.4	346.5	+12.5	460.2	+8.6	466.8	+1.4	
Domestic		329.2	85.2	165.3	254.2	349.5	83.9	(1.5)	179.1	+8.3	275.4	+8.3	378.0	+8.2	379.0	+0.3	
Oncology		172.4	45.4	87.2	135.8	188.9	47.7	+5.1	101.8	+16.7	156.9	+15.5	215.7	+14.2	220.3	+2.1	
Avastin		75.4	20.1	38.2	59.4	82.3	20.9	+4.0	44.3	+16.0	68.2	+14.8	93.8	+14.0	93.4	(0.4)	
Herceptin		30.9	8.1	14.9	22.9	31.2	7.5	(7.4)	15.8	+6.0	24.1	+5.2	32.7	+4.8	34.9	+6.7	
Rituxan		26.2	6.4	12.0	18.9	26.2	6.4	0.0	13.6	+13.3	21.0	+11.1	29.0	+10.7	32.9	+13.4	
Tarceva		10.4	2.9	5.6	8.4	11.5	2.5	(13.8)	5.5	(1.8)	8.6	+2.4	11.6	+0.9	12.5	+7.8	
Xeloda		11.3	2.8	5.0	7.6	10.4	2.6	(7.1)	5.3	+6.0	8.1	+6.6	11.1	+6.7	12.6	+13.5	
Perjeta		2.4	2.0	4.3	6.6	9.1	2.3	+15.0	5.0	+16.3	7.8	+18.2	10.6	+16.5	11.3	+6.6	
Kadcyla		-	-	1.0	2.4	4.0	1.5	-	3.4	+240.0	5.3	+120.8	7.3	+82.5	7.6	+4.1	
Alecensa		-	-	-	0.2	1.4	1.3	-	3.1	-	5.1	+2,450.0	8.0	+471.4	9.6	+20.0	
Neutrogin		8.1	1.3	2.8	4.2	5.9	1.0	(23.1)	2.3	(17.9)	3.6	(14.3)	4.9	(16.9)	2.9	(40.8)	
Zelboraf		-	-	-	-	-	0.1	-	0.2	-	0.3	-	0.5	-	0.7	+40.0	
Other products		7.6	1.8	3.4	5.1	6.9	1.6	(11.1)	3.3	(2.9)	4.7	(7.8)	6.1	(11.6)	1.8	(70.5)	
Bone and joint diseases		60.6	17.6	33.0	50.3	69.6	17.6	0.0	37.5	+13.6	57.5	+14.3	79.4	+14.1	85.8	+8.1	
Actemra		20.4	5.9	11.2	17.4	24.1	5.9	0.0	12.6	+12.5	19.4	+11.5	26.8	+11.2	29.7	+10.8	
Edirol		15.0	5.0	8.7	13.6	19.2	4.9	(2.0)	10.6	+21.8	16.4	+20.6	23.1	+20.3	25.6	+10.8	
Suvenyl		11.9	2.6	5.2	7.9	10.7	2.3	(11.5)	5.1	(1.9)	7.7	(2.5)	10.5	(1.9)	9.5	(9.5)	
Bonviva		0.5	0.7	1.3	2.3	3.4	1.1	+57.1	2.4	+84.6	3.8	+65.2	5.4	+58.8	7.7	+42.6	
Alfarol		6.4	1.2	2.5	3.7	4.9	1.0	(16.7)	2.1	(16.0)	3.1	(16.2)	4.2	(14.3)	3.1	(26.2)	
Other products		6.3	2.1	4.0	5.5	7.4	2.4	+14.3	4.7	+17.5	7.0	+27.3	9.5	+28.4	10.2	+7.4	
Renal diseases		48.9	11.7	21.5	32.9	44.7	9.9	(15.4)	21.4	(0.5)	33.1	+0.6	45.4	+1.6	40.8	(10.1)	
Mircera		22.5	5.9	10.8	16.5	22.6	5.0	(15.3)	11.0	+1.9	17.1	+3.6	23.8	+5.3	23.7	(0.4)	
Oxarol		12.2	3.0	5.8	8.9	12.2	2.8	(6.7)	6.0	+3.4	9.4	+5.6	12.9	+5.7	9.2	(28.7)	
Epogin		10.5	1.8	3.3	4.9	6.6	1.4	(22.2)	2.9	(12.1)	4.4	(10.2)	5.9	(10.6)	5.3	(10.2)	
Other products		3.7	0.9	1.6	2.5	3.4	0.7	(22.2)	1.4	(12.5)	2.1	(16.0)	2.8	(17.6)	2.5	(10.7)	
Transplant, Immunology, and Infectious diseases		18.8	4.7	10.6	16.1	20.8	3.4	(27.7)	7.1	(33.0)	11.5	(28.6)	15.9	(23.6)	14.1	(11.3)	
CellCept		7.2	1.6	3.2	4.8	6.5	1.6	0.0	3.3	+3.1	5.0	+4.2	7.0	+7.7	8.1	+15.7	
Pegasys		5.5	1.5	3.7	5.7	7.0	0.8	(46.7)	1.3	(64.9)	1.7	(70.2)	1.9	(72.9)	0.9	(52.6)	
Copegus		1.3	0.6	1.7	2.6	3.1	0.2	(66.7)	0.6	(64.7)	1.8	(30.8)	2.9	(6.5)	1.5	(48.3)	
Other products		4.8	1.0	2.0	3.1	4.2	0.9	(10.0)	2.0	0.0	3.0	(3.2)	4.0	(4.8)	3.6	(10.0)	
Others		28.6	5.9	13.0	19.1	25.6	5.3	(10.2)	11.4	(12.3)	16.5	(13.6)	21.7	(15.2)	18.0	(17.1)	
Sigmart		8.6	1.7	3.3	4.8	6.4	1.3	(23.5)	2.6	(21.2)	3.9	(18.8)	5.2	(18.8)	4.0	(23.1)	
Other products		20.0	4.2	9.7	14.3	19.2	4.0	(4.8)	8.8	(9.3)	12.6	(11.9)	16.6	(13.5)	14.0	(15.7)	
Overseas		61.1	22.1	35.7	53.7	74.3	22.8	+3.2	46.8	+31.1	71.1	+32.4	82.2	+10.6	87.8	+6.8	
Actemra		43.2	17.0	26.5	39.9	55.7	18.3	+7.6	37.7	+42.3	56.9	+42.6	63.6	+14.2	69.3	+9.0	
To Roche		42.9	16.9	26.3	39.5	55.1	18.0	+6.5	37.2	+41.4	56.1	+42.0	62.6	+13.6	68.0	+8.6	
Neutrogin		14.7	4.2	7.7	11.5	15.7	3.7	(11.9)	7.4	(3.9)	11.4	(0.9)	14.8	(5.7)	13.1	(11.5)	
Aloxi		-	-	-	-	-	0.1	-	0.1	-	0.2	-	0.3	-	0.1	(66.7)	
Alecensa		-	-	-	-	-	-	-	-	-	0.2	-	0.5	-	2.5	+400.0	
Akynzeo		-	-	-	-	-	-	-	-	-	0.0	-	0.0	-	0.2	-	
Other products		3.1	0.8	1.6	2.3	2.9	0.8	0.0	1.6	0.0	2.4	+4.3	3.0	+3.4	2.6	(13.3)	
Tamiflu		11.0	6.9	7.1	7.2	13.0	6.7	(2.9)	6.7	(5.6)	6.7	(6.9)	8.2	(36.9)	8.6	+4.9	
Ordinary use		10.1	6.8	7.0	7.0	12.9	6.7	(1.5)	6.7	(4.3)	6.7	(4.3)	8.2	(36.4)	7.6	(7.3)	
Govt. stockpiles etc.		0.9	0.1	0.1	0.2	0.2	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	1.0	-	
Royalties and other operating income		22.4	9.8	13.9	18.3	24.2	3.7	(62.2)	7.5	(46.0)	14.5	(20.8)	30.4	+25.6	19.6	(35.5)	
Revenues		423.7	124.0	222.0	333.4	461.1	117.1	(5.6)	240.2	+8.2	367.8	+10.3	498.8	+8.2	495.0	(0.8)	
Domestic		350.8	98.7	179.6	269.1	372.9	90.8	(8.0)	186.2	+3.7	282.6	+5.0	390.0	+4.6	389.5	(0.1)	
Overseas		72.9	25.3	42.5	64.3	88.2	26.2	+3.6	53.9	+26.8	85.1	+32.3	108.8	+23.4	105.5	(3.0)	

Statements of revenues (QTR)

(Billions of yen)

		Actual				Actual							
		FY2014				FY2015							
		1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
		QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Sales		114.2	93.9	107.0	121.7	113.4	(0.7)	119.2	+26.9	120.6	+12.7	115.2	(5.3)
	Excl. Tamiflu	107.3	93.7	106.9	115.9	106.7	(0.6)	119.2	+27.2	120.6	+12.8	113.7	(1.9)
	Domestic	85.2	80.1	88.9	95.3	83.9	(1.5)	95.2	+18.9	96.3	+8.3	102.6	+7.7
	Oncology	45.4	41.8	48.6	53.1	47.7	+5.1	54.1	+29.4	55.1	+13.4	58.8	+10.7
	Avastin	20.1	18.1	21.2	22.9	20.9	+4.0	23.4	+29.3	23.9	+12.7	25.6	+11.8
	Herceptin	8.1	6.9	8.0	8.3	7.5	(7.4)	8.4	+21.7	8.3	+3.8	8.6	+3.6
	Rituxan	6.4	5.6	6.9	7.2	6.4	0.0	7.2	+28.6	7.4	+7.2	7.9	+9.7
	Tarceva	2.9	2.7	2.8	3.0	2.5	(13.8)	3.0	+11.1	3.1	+10.7	3.0	0.0
	Xeloda	2.8	2.3	2.6	2.8	2.6	(7.1)	2.8	+21.7	2.8	+7.7	3.0	+7.1
	Perjeta	2.0	2.2	2.3	2.5	2.3	+15.0	2.7	+22.7	2.8	+21.7	2.8	+12.0
	Kadcyla	—	1.0	1.4	1.7	1.5	—	1.9	+90.0	1.9	+35.7	2.0	+17.6
	Alecensa	—	—	0.2	1.2	1.3	—	1.7	—	2.1	+950.0	2.8	+133.3
	Neutrogin	1.3	1.5	1.5	1.7	1.0	(23.1)	1.3	(13.3)	1.3	(13.3)	1.3	(23.5)
	Zelboraf	—	—	—	—	0.1	—	0.1	—	0.2	—	0.2	—
	Other products	1.8	1.6	1.7	1.8	1.6	(11.1)	1.7	+6.3	1.4	(17.6)	1.4	(22.2)
	Bone and joint diseases	17.6	15.4	17.4	19.2	17.6	0.0	19.8	+28.6	20.1	+15.5	21.8	+13.5
	Actemra	5.9	5.3	6.2	6.7	5.9	0.0	6.7	+26.4	6.8	+9.7	7.4	+10.4
	Edirol	5.0	3.7	4.9	5.5	4.9	(2.0)	5.7	+54.1	5.8	+18.4	6.6	+20.0
	Suvenyl	2.6	2.7	2.6	2.8	2.3	(11.5)	2.7	0.0	2.6	0.0	2.8	0.0
	Bonviva	0.7	0.6	0.9	1.1	1.1	+57.1	1.3	+116.7	1.4	+55.6	1.6	+45.5
	Alfarol	1.2	1.2	1.2	1.2	1.0	(16.7)	1.1	(8.3)	1.0	(16.7)	1.1	(8.3)
	Other products	2.1	1.9	1.5	1.9	2.4	+14.3	2.3	+21.1	2.3	+53.3	2.4	+26.3
	Renal diseases	11.7	9.8	11.4	11.9	9.9	(15.4)	11.5	+17.3	11.7	+2.6	12.3	+3.4
	Mircera	5.9	4.9	5.7	6.1	5.0	(15.3)	6.0	+22.4	6.1	+7.0	6.7	+9.8
	Oxarol	3.0	2.7	3.1	3.3	2.8	(6.7)	3.2	+18.5	3.4	+9.7	3.5	+6.1
	Epogin	1.8	1.5	1.6	1.6	1.4	(22.2)	1.5	0.0	1.5	(6.3)	1.5	(6.3)
	Other products	0.9	0.7	0.9	0.8	0.7	(22.2)	0.7	0.0	0.7	(22.2)	0.7	(12.5)
	Transplant, Immunology, and Infectious diseases	4.7	5.9	5.5	4.7	3.4	(27.7)	3.7	(37.3)	4.3	(21.8)	4.4	(6.4)
	CellCept	1.6	1.6	1.6	1.8	1.6	0.0	1.7	+6.3	1.8	+12.5	1.9	+5.6
	Pegasys	1.5	2.1	2.0	1.3	0.8	(46.7)	0.6	(71.4)	0.4	(80.0)	0.2	(84.6)
	Copegus	0.6	1.1	0.9	0.5	0.2	(66.7)	0.4	(63.6)	1.2	+33.3	1.2	+140.0
	Other products	1.0	1.0	1.0	1.1	0.9	(10.0)	1.0	0.0	1.0	0.0	1.1	0.0
	Others	5.9	7.1	6.1	6.5	5.3	(10.2)	6.1	(14.1)	5.1	(16.4)	5.2	(20.0)
	Sigmat	1.7	1.6	1.5	1.6	1.3	(23.5)	1.3	(18.8)	1.3	(13.3)	1.3	(18.8)
	Other products	4.2	5.5	4.6	4.9	4.0	(4.8)	4.8	(12.7)	3.8	(17.4)	3.9	(20.4)
	Overseas	22.1	13.6	18.0	20.6	22.8	+3.2	24.0	+76.5	24.3	+35.0	11.1	(46.1)
	Actemra	17.0	9.5	13.4	15.8	18.3	+7.6	19.4	+104.2	19.2	+43.3	6.7	(57.6)
	To Roche	16.9	9.3	13.2	15.6	18.0	+6.5	19.2	+106.5	18.9	+43.2	6.5	(58.3)
	Neutrogin	4.2	3.4	3.8	4.2	3.7	(11.9)	3.7	+8.8	4.0	+5.3	3.5	(16.7)
	Aloxi	—	—	—	—	0.1	—	0.0	—	0.1	—	0.1	—
	Alecensa	—	—	—	—	—	—	—	—	0.2	—	0.3	—
	Akynzeo	—	—	—	—	—	—	—	—	0.0	—	0.0	—
	Other products	0.8	0.7	0.8	0.6	0.8	0.0	0.9	+28.6	0.8	0.0	0.6	0.0
	Tamiflu	6.9	0.2	0.1	5.8	6.7	(2.9)	0.0	(100.0)	0.0	(100.0)	1.5	(74.1)
	Ordinary use	6.8	0.2	0.0	5.8	6.7	(1.5)	0.0	(100.0)	0.0	0.0	1.5	(74.1)
	Govt. stockpiles etc.	0.1	—	0.1	0.0	0.0	(100.0)	—	—	—	(100.0)	0.0	0.0
Royalties and other operating income		9.8	4.1	4.4	5.9	3.7	(62.2)	3.9	(4.9)	7.0	+59.1	15.9	+169.5
Revenues		124.0	98.0	111.4	127.7	117.1	(5.6)	123.1	+25.6	127.6	+14.5	131.1	+2.7
	Domestic	98.7	80.8	89.5	103.8	90.8	(8.0)	95.4	+18.1	96.4	+7.7	107.4	+3.5
	Overseas	25.3	17.2	21.9	23.9	26.2	+3.6	27.7	+61.0	31.2	+42.5	23.7	(0.8)

Movements of assets and liabilities (Assets, Liabilities, and Net Assets)

(Billions of yen)

	Actual	Actual				Actual											
	FY2013	FY2014				FY2015											
	Dec. 31	Mar. 31	Jun. 30	Sep. 30	Dec. 31	Mar. 31	vs. Mar. 31, 2014	vs. Dec. 31, 2014	Jun. 30	vs. Jun. 30, 2014	vs. Dec. 31, 2014	Sep. 30	vs. Sep. 30, 2014	vs. Dec. 31, 2014	Dec. 31	vs. Dec. 31, 2014	
Trade accounts receivable	111.1	121.4	106.6	120.9	141.3	120.6	(0.8)	(20.7)	128.3	21.7	(13.0)	126.1	5.2	(15.2)	134.5	(6.8)	
Inventories	128.5	129.5	141.8	151.0	139.6	147.8	18.3	8.2	145.9	4.1	6.3	154.3	3.3	14.7	161.1	21.5	
Trade accounts payable	(35.9)	(43.9)	(42.9)	(42.1)	(35.4)	(49.2)	(5.3)	(13.8)	(43.4)	(0.5)	(8.0)	(46.2)	(4.1)	(10.8)	(41.2)	(5.8)	
Other net working capital	(26.6)	(19.9)	(21.1)	(29.6)	(36.2)	(30.1)	(10.2)	6.1	(26.2)	(5.1)	10.0	(31.5)	(1.9)	4.7	(39.8)	(3.6)	
Net working capital	177.1	187.0	184.4	200.2	209.4	189.0	2.0	(20.4)	204.6	20.2	(4.8)	202.7	2.5	(6.7)	214.6	5.2	
Property, plant and equipment	140.4	139.4	140.0	139.1	140.2	140.7	1.3	0.5	141.9	1.9	1.7	142.8	3.7	2.6	153.5	13.3	
Intangible assets	9.5	9.4	9.6	10.4	11.3	11.8	2.4	0.5	10.9	1.3	(0.4)	13.3	2.9	2.0	13.5	2.2	
Other long-term assets – net	(1.8)	(1.9)	(1.6)	(3.2)	(3.2)	(3.1)	(1.2)	0.1	(2.1)	(0.5)	1.1	(2.7)	0.5	0.5	(1.3)	1.9	
Long-term net operating assets	148.1	147.0	147.9	146.3	148.4	149.4	2.4	1.0	150.7	2.8	2.3	153.4	7.1	5.0	165.8	17.4	
Net operating assets	325.2	333.9	332.3	346.4	357.7	338.4	4.5	(19.3)	355.3	23.0	(2.4)	356.2	9.8	(1.5)	380.4	22.7	
Debt	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)	0.0	0.0	(0.2)	0.0	0.0	(0.8)	(0.6)	(0.6)	(0.7)	(0.5)	
Marketable securities	119.6	115.5	115.1	114.9	116.0	114.3	(1.2)	(1.7)	120.0	4.9	4.0	121.7	6.8	5.7	134.4	18.4	
Cash and cash equivalents	115.1	115.0	128.8	108.1	114.0	123.6	8.6	9.6	126.6	(2.2)	12.6	121.6	13.5	7.6	101.7	(12.3)	
Net cash	234.4	230.3	243.6	222.8	229.9	237.8	7.5	7.9	246.4	2.8	16.5	242.5	19.7	12.6	235.4	5.5	
Other non-operating assets – net	13.6	13.1	9.5	14.5	10.2	18.8	5.7	8.6	11.7	2.2	1.5	16.4	1.9	6.2	11.5	1.3	
Net non-operating assets	248.0	243.4	253.1	237.3	240.0	256.6	13.2	16.6	258.2	5.1	18.2	258.9	21.6	18.9	246.8	6.8	
Total net assets	573.2	577.4	585.4	583.7	597.8	594.9	17.5	(2.9)	613.4	28.0	15.6	615.1	31.4	17.3	627.3	29.5	
Total net assets																	
Total assets	697.2	701.6	708.2	713.9	739.5	727.3	25.7	(12.2)	744.3	36.1	4.8	753.5	39.6	14.0	787.4	47.9	
Total liabilities	(124.0)	(124.2)	(122.8)	(130.2)	(141.8)	(132.3)	(8.1)	9.5	(130.9)	(8.1)	10.9	(138.4)	(8.2)	3.4	(160.1)	(18.3)	
Attributable to																	
Chugai shareholders	571.7	576.0	584.4	582.4	596.1	593.8	17.8	(2.3)	612.6	28.2	16.5	613.9	31.5	17.8	625.9	29.8	
Non-controlling interests	1.5	1.4	1.0	1.3	1.7	1.2	(0.2)	(0.5)	0.9	(0.1)	(0.8)	1.1	(0.2)	(0.6)	1.4	(0.3)	

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets – net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets – net: deferred income tax assets, current income tax liabilities etc.

Movements of assets and liabilities

The consolidated balance sheet has been prepared in accordance with the IAS No. 1, “Presentation of Financial Statements.” On the other hand, “Movements of assets and liabilities” including net operating assets (NOA) are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from the assets and liabilities of IFRS have been excluded, as the Core results concept only applies to the income statement.

Movements of free cash flows

(Billions of yen)

	Actual	Actual				Actual			
	FY2013	FY2014				FY2015			
	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD
Operating profit – IFRS basis	78.7	31.1	43.1	59.1	75.9	20.7	43.2	67.1	86.8
Depreciation and impairment of property, plant and equipment	15.2	3.4	6.8	12.0	15.5	3.5	7.0	10.5	14.2
Amortization and impairment of intangible assets	1.1	0.3	0.6	0.9	1.4	0.7	2.6	3.0	3.5
Other cash adjustment on operating profit	2.3	1.4	1.4	3.2	3.7	0.2	(0.7)	(0.0)	1.0
Operating profit, net of operating cash adjustments	97.3	36.1	51.9	75.2	96.4	25.0	52.1	80.6	105.4
(Increase) decrease in trade accounts receivable	4.9	(10.3)	4.5	(9.8)	(30.2)	20.6	13.0	15.1	6.7
(Increase) decrease in inventories	(20.5)	(1.9)	(14.3)	(23.6)	(12.2)	(8.5)	(6.7)	(15.5)	(23.3)
Increase (decrease) in trade accounts payable	(6.0)	8.0	7.0	6.2	(0.6)	13.9	8.0	10.9	5.9
Change in other net working capital etc.	1.9	(3.2)	(2.8)	4.6	9.7	(4.5)	(7.3)	(1.1)	(5.2)
Total (increase) decrease in net working capital etc.	(19.7)	(7.4)	(5.6)	(22.6)	(33.3)	21.4	7.0	9.4	(15.9)
Investment in property, plant and equipment	(11.3)	(5.6)	(9.2)	(12.1)	(16.2)	(5.1)	(10.9)	(15.5)	(18.4)
Investment in intangible assets	(3.4)	(0.7)	(1.3)	(2.4)	(2.9)	(2.1)	(2.9)	(5.9)	(6.5)
Operating free cash flow	63.0	22.4	35.8	38.0	43.9	39.2	45.3	68.6	64.6
as % of revenues	14.9%	18.1%	16.1%	11.4%	9.5%	33.5%	18.9%	18.7%	13.0%
Treasury activities (interest income/expenses, foreign exchange gains/losses etc.)	(0.2)	(0.3)	0.4	0.6	0.3	1.7	2.6	3.0	1.6
Tax paid	(23.8)	(12.9)	(13.3)	(24.8)	(25.2)	(15.5)	(16.0)	(28.2)	(29.1)
Dividends paid	(23.9)	(12.8)	(12.9)	(25.4)	(25.5)	(14.6)	(14.8)	(29.3)	(29.4)
Free cash flow	15.0	(3.6)	10.0	(11.5)	(6.5)	10.8	17.2	14.2	7.6
Transaction in own equity instruments	0.8	0.3	0.5	0.9	1.2	0.4	0.8	1.3	1.4
Net effect of currency translation on net cash	6.9	(0.8)	(1.3)	(1.0)	0.7	(3.2)	(1.4)	(2.8)	(3.5)
Net change in net cash	22.7	(4.1)	9.2	(11.6)	(4.5)	7.9	16.5	12.6	5.5

Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) (including proceeds from the sales of assets and reserve payments).

Operating free cash flow (FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,” which shows the company’s cash generation ability from operating activities.

Free cash flow: the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: increases and decreases in marketable securities and interest-bearing debt are included.

The concepts of operating profit, operating FCF and movements of assets and liabilities including NOA presented in the previous page are mutually consistent.

Movements of free cash flows

The consolidated statement of cash flows has been prepared in accordance with the IAS No. 7, “Statement of Cash Flows.” The FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from the FCF have been excluded, as the Core results concept only applies to the income statement.

Performance indicators

	Units	Actual	Actual					Actual				Forecast (Jan 28th announced)
		FY2013	FY2014					FY2015				FY2016
		1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12	1-12
		As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31	As of Dec. 31
Ratio of net income to equity attributable to Chugai shareholders (ROE)	%	9.3	3.3	5.0	6.9	8.7	2.5	5.0	7.9	10.0		
Ratio of profit before taxes to total assets (ROA)	%	11.5	4.5	6.2	8.4	10.6	2.9	5.9	9.0	11.4		
Ratio of equity attributable to Chugai shareholders	%	82.0	82.1	82.5	81.6	80.6	81.6	82.3	81.5	79.5		
Equity per share attributable to Chugai shareholders (BPS)	Yen	1,049.47	1,057.03	1,072.08	1,068.10	1,092.90	1,088.25	1,122.33	1,124.39	1,146.17		
Ratio of dividends to equity attributable to Chugai shareholders (DOE)	%	4.5	4.5					5.2				
Core return on net operating assets (Core RONO A)	%	16.2	5.8	9.0	11.9	14.8	4.5	9.2	14.2	17.1		
Cash conversion cycle (CCC)	Months	9.3	7.8	8.9	9.7	9.6	8.3	8.6	8.7	9.4		
Net cash turnover period	Months	6.6	5.6	6.6	6.0	6.0	6.1	6.2	5.9	5.7		
Number of employees		6,872	6,904	7,036	7,027	7,023	7,009	7,196	7,177	7,169		
Investment on property, plant and equipment	Billions of yen	13.0	2.5	6.5	11.4	16.3	4.0	7.8	13.5	28.7	19.0	
Depreciation	Billions of yen	13.5	3.4	6.8	10.2	13.7	3.4	6.9	10.4	14.0	14.5	
Investment on intangible assets	Billions of yen	4.0				3.1				5.8		
Amortization	Billions of yen	1.0				1.2				1.6		

Core RONO A: Core operating profit / Net operating assets

CCC: [Trade accounts receivable/Sales + (Inventories - Trade accounts payable)/Cost of sales]* passed months

Net cash turnover period: Net cash/Revenue* passed months

Ratio of net income to equity attributable to Chugai shareholders (ROE), Ratio of profit before taxes to total assets (ROA), and Core return on net operating assets (Core RONO A) are not annualized.

Major capital investments plan

(Domestic subsidiary : Chugai Pharma Manufacturing Co., Ltd.)

(Billions of yen)

Facilities (Location)	Description	Planned investment		Fund raising method	Start of construction	Slated completion date
		Total amount	Investment to-date			
Utsunomiya plant (Utsunomiya-city, Tochigi)	Enhancement of high-mix low-volume production capability for pre-filled syringe form products (Installment of tray filler)	6.0	3.3	Self-financing	September 2013	July 2017
Ukima plant (Kita-district, Tokyo)	Enhancement of high-mix low-volume production of antibody API for initial commercial products (Expansion of production capability)	37.2	10.0	Self-financing	November 2015	May 2019
Fujieda plant (Fujieda-city, Shizuoka)	Strengthening of solid formulation manufacturing facility, etc. (React to quick launch and steady supply)	6.0	0.9	Self-financing	November 2015	December 2018

Plan concerning “Enhancement of high-mix low-volume production capability for pre-filled syringe form products (Installment of tray filler)” has been entirely transferred to Chugai Pharma Manufacturing Co., Ltd. in 2015.

Development pipeline (as of January 28, 2016)

Development code (Compound number)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Oncology</u>					
RG340 (Ro09-1978)	Gastric cancer (adjuvant) #	Approved (15/11)	capecitabine Xeloda Oral	Roche Xeloda (Yakult Honsha)	Antimetabolite, 5-FU derivative
AF802 / RG7853 (CH5424802/RO5424802)	Non-small cell lung cancer (NSCLC) [post-crizotinib]	Approved (15/12) US	alectinib Alecensa Oral	In-house Alecensa (Roche)	ALK inhibitor
		Filed (15/09) Europe			
	NSCLC [1st line]	Phase III Overseas			
RG435 (RO4876646)	Cervical Cancer #	Filed (15/09)	bevacizumab Avastin Injection	Roche Avastin	Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody
	Renal cell carcinoma #	Phase III Multinational study			
RG1273 (RO4368451)	Breast cancer (adjuvant) #	Phase III Multinational study	pertuzumab Perjeta Injection	Roche Perjeta	HER2 dimerization inhibitory humanized monoclonal antibody
	Gastric cancer #	Phase III Multinational study			
RG3502 (RO5304020)	Breast cancer (adjuvant) #	Phase III Multinational study	trastuzumab emtansine Kadcyla Injection	Roche Kadcyla	Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
	Gastric cancer #	Development discontinued			
GA101 / RG7159 (RO5072759)	Aggressive non-Hodgkin's lymphoma (NHL)	Phase III Multinational study	obinutuzumab Injection	Roche Gazyva/Gazyvaro (EU) (Nippon Shinyaku)	Glycoengineered type II anti-CD20 monoclonal antibody
	Indolent NHL	Phase III Multinational study			

Development code (Compound number)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG7446 (MPDL3280A)	NSCLC	Phase III Multinational study	atezolizumab Injection	Roche	Engineered anti-PDL1 monoclonal antibody
	NSCLC (adjuvant)	Phase III Multinational study			
	Bladder cancer	Phase III Multinational study			
	Muscle Invasive bladder Cancer (adjuvant)	Phase III Multinational study			
	Renal cell carcinoma	Phase III Multinational study			
GC33 / RG7686 (GC33/RO5137382)	Hepatocellular carcinoma	Phase II Multinational study	codrituzumab Injection	In-house (Roche)	Anti-Glypican-3 humanized monoclonal antibody
CKI27 / RG7304 (RO5126766)	Solid tumors	Phase I	Oral	In-house	Raf and MEK dual inhibitor
		Phase I Overseas		(Roche)	
RG7596 (RO5541077)	NHL	Phase I	polatuzumab vedotin Injection	Roche	Anti-CD79b antibody-drug conjugate
RG7604 (GDC-0032)	Solid tumors	Phase I	taselisib Oral	Roche	PI3K inhibitor
RG7440 (GDC-0068)	Solid tumors	Phase I	ipatasertib Oral	Roche/Array BioPharma	AKT inhibitor
<u>Bone and Joint Diseases</u>					
RG484 (Ro200-5450po)	Osteoporosis	Approved (16/01)	ibandronic acid Bonviva Oral	Roche Bonviva/Boniva (US) (Taisho Pharmaceutical)	Bisphosphonate
ED-71 (ED-71)	Osteoporosis	Phase III China	eldecalcitol Edirol Oral	In-house	Activated vitamin D ₃ agent

Development code (Compound number)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Renal Diseases</u>					
EOS789 (EOS789)	Hyperphosphatemia	Phase I	Oral	In-house	-
<u>Autoimmune Diseases</u>					
MRA / RG1569 (RO4877533)	Large-vessel vasculitis #	Phase III	tocilizumab Actemra	In-house Actemra/RoActemra (EU) (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
	Giant cell arteritis #	Phase III Overseas	Injection		
	Systemic sclerosis #	Phase III Multinational study			
SA237 (SA237)	Neuromyelitis optica (NMO)	Phase III Multinational study*	Injection	In-house	Anti-IL-6 receptor humanized monoclonal antibody
<u>Central Nervous System</u>					
RG1450 (RO4909832)	Alzheimer's disease	Phase III Multinational study	gantenerumab Injection	Roche/MorphoSys	Anti-amyloid-beta human monoclonal antibody
RG1662 (RO5186582)	Improvement of intellectual ability in individuals with Down syndrome	Phase I	basmisanil Oral	Roche	GABAAα5 receptor antagonist
<u>Respiratory Diseases</u>					
RG3637 (RO5490255)	Asthma	Phase III Multinational study	lebrikizumab	Roche	Anti-IL-13 humanized monoclonal antibody
	Idiopathic pulmonary fibrosis	Phase II Multinational study	Injection		
<u>Others</u>					
ACE910 / RG6013 (RO5534262)	Hemophilia A	Phase III Multinational study	emicizumab Injection	In-house (Roche)	Anti-FIXa/FX bispecific antibody
CIM331 (CIM331)	Atopic dermatitis	Phase II Multinational study*	nemolizumab	In-house	Anti-IL-31 receptor humanized monoclonal antibody
	Pruritus in dialysis patients	Phase II	Injection		

Development code (Compound number)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
URC102 (URC102)	Gout	Phase II Overseas	Oral	In-house/JW Pharmaceutical (JW Pharmaceutical)	URAT1 inhibitor
PCO371 (PCO371)	Hypoparathyroidism	Phase I Overseas	Oral	In-house	PTH1 receptor agonist

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

* Multinational study managed by Chugai

Changes from the last announcement on January 28, 2016

Oncology

- RG340 Filed → Approved (Gastric cancer (adjuvant))
- AF802/RG7853 Filed → Approved (US, NSCLC (post-crizotinib))
- RG7446 Phase III multinational study (NSCLC (adjuvant): Development started)
- Phase III multinational study (Muscle invasive bladder cancer (adjuvant): Development started)
- RG3502 Phase II/III multinational study → Development discontinued (Gastric cancer)

Bone and Joint Diseases

- RG484 Filed → Approved (Osteoporosis)

Renal Diseases

- MRA/RG1596 Phase II (Overseas) → Phase III multinational study (Systemic sclerosis)

Others

- ACE910/RG6013 Phase I/II → Phase III multinational study (Hemophilia A)

R&D Activities (Jan. 1, 2015 - Jan. 28, 2016)

As for clinical development activities, Chugai saw progress as described below:

Oncology

- We launched the BRAF inhibitor RG7204 (product name: Zelboraf) for the indication of unresectable melanoma with *BRAF* mutation in February, 2015.
- We started Phase III multinational studies for the engineered anti-PDL1 monoclonal antibody RG7446 for the expected indication of bladder cancer in January, renal cell carcinoma in June, adjuvant treatment for muscle invasive bladder cancer in November, and adjuvant treatment for NSCLC in December, all in 2015.
- We started a Phase II study in January and filed an application for approval for the anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody (product name: Avastin) for the expected indication of cervical cancer in September, 2015. We also started a Phase III multinational study (expected indication: renal cell carcinoma) in June, 2015.
- We started a Phase I study (expected indication: solid tumors) for the AKT inhibitor RG7440 in June, 2015.
- We filed an application for the ALK inhibitor AF802/RG7853 in July and obtained approval in December in the US for the indication of anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or those intolerant to crizotinib in 2015. Application was filed in Europe for the same indication in September, 2015.
- We obtained approval for the antimetabolite, 5-FU derivative, RG340 (product name: Xeloda) for the indication of adjuvant treatment for gastric cancer in November, 2015.
- We decided to discontinue development of the PI3K inhibitor, RG7321 in consideration of Roche's decision to remove the project from the pipeline. A Phase I study had been in progress for solid tumors.
- We decided to discontinue development of the anti-HER2 antibody-tubulin polymerization inhibitor conjugate RG3502 for gastric cancer in consideration of the fact that the primary endpoint was not achieved in the multinational Phase III study (the GATSBY study).

Bone and Joint Diseases

- We filed an application for the expected indication of osteoporosis for bisphosphonate, RG484 (oral) in February, 2015 and obtained approval in January, 2016.
- We started a Phase III study (expected indication: osteoporosis) for the activated vitamin D₃ agent, ED-71 in China in August, 2015.

Renal diseases

- We started a Phase I study (expected indication: hyperphosphatemia) for EOS789 in September, 2015.

Autoimmune diseases

- We started a multinational Phase III study (expected indication: systemic sclerosis) for the humanized anti-human IL-6 receptor monoclonal antibody MRA/RG1596 in November, 2015.

Central Nervous System

- We decided to discontinue development of the mGluR5 antagonist RG7090 in consideration of results from a global Phase II study for major depression.
- We decided to discontinue development of the MAO-B inhibitor RG1577 in consideration of results from overseas studies conducted by Roche for Alzheimer's disease.

Others

- We started a Phase I study (expected indication: hypoparathyroidism) for the PTH1 receptor agonist PCO371 in June, 2015.
- We started a Phase II study (expected indication: pruritus in dialysis patients) for the anti-IL31 humanized receptor antibody CIM 331 in August, 2015.
- We started a multinational Phase III study (expected indication: hemophioia A) for the anti-FIXa/FX bispecific antibody ACE910/RG6013 in November, 2015.

Major clinical trials in oncology field currently running in Japan

Theme	Expected Indication	Regimen	Stage	Planned filing date
RG1273 (pertuzumab) Perjeta	Breast cancer (adjuvant)	Herceptin + chemotherapy ± RG1273	APHINITY study Phase III multinational study	2017
	Gastric cancer	Herceptin + chemotherapy ± RG1273	JACOB study Phase III multinational study	2018 and beyond
RG3502 (trastuzumab emtansine) Kadcyla	Breast cancer (adjuvant)	Kadcyla + Perjeta vs. Herceptin + Perjeta + chemotherapy	KAITLIN study Phase III multinational study	2018 and beyond
GA101/ RG7159 (obinutuzumab)	Aggressive NHL	GA101 + CHOP vs. Rituxan + CHOP (G-CHOP vs R-CHOP)	GOYA study Phase III multinational study	2017
	Indolent NHL	GA101 + chemotherapy vs. Rituxan + chemotherapy (G-chemo vs R-chemo)	GALLIUM study Phase III multinational study	2017
RG7446 (atezolizumab)	NSCLC	RG7446 vs docetaxel	OAK study Phase III multinational study	2017
		RG7446	BIRCH study Phase II multinational study	
		Non-squamous, PD-L1 positive RG7446 vs. chemotherapy	IMpower 110 study Phase III multinational study	
		Non-squamous RG7446 + chemotherapy ± Avastin vs. Chemotherapy + Avastin	IMpower 150 study Phase III multinational study	
		Squamous Chemotherapy ± RG7446	IMpower 131 study Phase III multinational study	
	NSCLC (adjuvant)	RG7446 vs. best supportive care	IMpower 010 study Phase III multinational study	2018 and beyond
	Bladder cancer	RG7446 vs chemotherapy	IMvigor 211 study Phase III multinational study	2017
	Muscle invasive bladder cancer (adjuvant)	RG7446 vs. observation	IMvigor 010 study Phase III multinational study	2018 and beyond
	Renal cell carcinoma	RG7446 + Avastin vs. sunitinib	IMmotion 151 study Phase III multinational study	2018 and beyond
RG435 (bevacizumab) Avastin	Cervical cancer	Avastin + chemotherapy	Filed	